Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to -$25.8 million.

  • Century Therapeutics' Free Cash Flow rose 901.1% to -$25.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.0 million, marking a year-over-year increase of 80.49%. This contributed to the annual value of -$110.3 million for FY2024, which is 803.75% down from last year.
  • Latest data reveals that Century Therapeutics reported Free Cash Flow of -$25.8 million as of Q3 2025, which was up 901.1% from -$27.9 million recorded in Q2 2025.
  • Century Therapeutics' Free Cash Flow's 5-year high stood at $82.7 million during Q1 2022, with a 5-year trough of -$36.0 million in Q2 2022.
  • For the 4-year period, Century Therapeutics' Free Cash Flow averaged around -$21.2 million, with its median value being -$27.9 million (2025).
  • Data for Century Therapeutics' Free Cash Flow shows a peak YoY increase of 5032.6% (in 2023) and a maximum YoY decrease of 14137.34% (in 2023) over the last 5 years.
  • Over the past 4 years, Century Therapeutics' Free Cash Flow (Quarter) stood at -$29.2 million in 2022, then rose by 6.74% to -$27.2 million in 2023, then rose by 10.98% to -$24.2 million in 2024, then fell by 6.42% to -$25.8 million in 2025.
  • Its Free Cash Flow stands at -$25.8 million for Q3 2025, versus -$27.9 million for Q2 2025 and -$35.1 million for Q1 2025.